[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-outlet-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-outlet-obstruction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,75,98,133,163,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100482428","enteral-anastomosis-for-the-treatment-of-gastric-outlet-obstruction-a-randomized-controlled-study-comparing-endoscopic-versus-surgical-gastrojejunostomy-100482428",false,"NCT05561907","Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy","EAT-GO","Inclusion Criteria:\n\n1. Periampullary malignancy (pancreas, bile duct, ampulla, duodenum) extending to the distal duodenum (D3) or distal (antrum) gastric cancer\n2. Symptoms of gastric outlet obstruction (at least 2 of 4 required):\n\n   1. post prandial vomiting,\n   2. abdominal pain,\n   3. inability to tolerate PO,\n   4. imaging consistent with GOO\n3. Gastric Outlet Obstruction Scoring System (GOOSS) Score of 0 (no oral intake) or 1 (liquids only)\n4. Age \\>18 years old\n5. Life expectancy greater than 2 months or failed duodenal stenting\n6. Surgical Candidate\u002FTolerate General Anesthesia\n7. Unresectable or metastatic disease\n\nExclusion Criteria:\n\n1. Age\\\u003C 18 years old\n2. Pregnancy\n3. Intestinal obstruction distal to the Ligament of Treitz\n4. Evidence of other luminal strictures of the GI tract\n5. Previous gastric or periampullary surgery\n6. Inability to complete quality of life surveys (QOLS)\n7. Presence of abdominal ascites","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","Gastric outlet obstruction (GOO) occurs commonly in malignancies involving the periampullary region (cancers originating in the head of the pancreas, duodenum, bile duct, or ampulla) or the distal stomach. GOO not only causes debilitating symptoms such as nausea, vomiting, inability to tolerate oral intake, and prevents adequate nutritional intake. Therefore, providing therapy for GOO is imperative to improve the quality of life, and nutritional status of these patients, as well as allow them to continue receiving their cancer treatment",[26],"Gastric Outlet Obstruction",[28,29,30,31,32,33,34,35],"Gastric outlet obstruction","GOO","Periampullary malignancy","Periampullary cancer","Surgical gastrojejunostomy","Endoscopic gastrojejunostomy","Gastrojejunostomy","Enteral anastamosis","RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":40},"2022-10-28",{"date":44,"type":20},"2027-06",{"name":46,"class":47},"Northwell Health","OTHER",4,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100637455","magnet-system-gastric-outlet-obstruction-study-100637455","NCT07609511","Magnet System Gastric Outlet Obstruction Study","Creation of Magnetic Compression Gastroenterostomy Using the GT Metabolic Solutions Magnet System in Adults With Gastric Outlet Obstruction (GOO): Magnet System GOO Study","Inclusion Criteria:\n\n* Gastric outlet obstruction (GOO) and indicated for a gastroenterostomy, per the discretion of the treating investigator.\n* If a child-bearing female, subject must commit to not becoming pregnant and agree to use contraception for the duration of the study.\n* Willing and able to comply with protocol requirements and provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the gastroenterostomy procedure.\n* If GOO due to malignant neoplasm:\n* Baseline Eastern Cooperative Oncology Group (ECOG) \\> 2 and\u002For Karnofsky Performance score \\\u003C 30\n* Gastric or intestinal cancer or malignant infiltration precluding creation of a magnetic compression anastomosis (per investigator discretion)\n* Coagulation disorders, on continuous or complete anticoagulation, or other conditions associated with high risk of bleeding and not correctable or manageable, precluding creation of a magnetic compression anastomosis (per investigator discretion)\n* Any anomaly precluding orogastric access by endoscope and catheters, and manipulation techniques.\n* Implantable pacemaker or defibrillator.\n* Woman who is either pregnant or breast feeding.\n* Any comorbidity or current status of subject's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the subject medically unfit for the procedure, including any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the Magnets.\n* Unhealed ulcers, bleeding lesions, tumor, or any other lesion at target Magnet deployment sites.\n* Expected need for Magnetic Resonance Imaging (MRI) within the first 2 months after the procedure.\n* Any anomaly preventing\u002Fcontraindicating endoscopic or laparoscopic access and procedures.\n* Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure.\n* Unable to comply with the follow-up schedule and assessments.\n* Known allergies to the device components or contrast media.\n* Currently participating in another clinical research study with an investigational drug or medical device.\n* Any condition that, in the investigator's opinion, may preclude completion of follow-up assessments through Day 90 (e.g., a medical condition that may increase the risk associated with study participation or may interfere with interpretation of study results, inability to adhere to the visit schedule, or poor compliance with treatment regimen.",{"count":57,"type":20},10,[23],"Evaluate the performance and safety of the GT Metabolic Magnet System to create side-to-side gastroenteral magnetic compression anastomosis (gastroenterostomy).",[26],[62,63],"Magnet System","GT Metabolic Solutions, Inc.","NOT_YET_RECRUITING","2026-05-21",{"date":67,"type":40},"2026-05-27",{"date":69,"type":20},"2026-07",{"date":71,"type":20},"2026-12",{"name":63,"class":73},"INDUSTRY",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":74},"100617319","gt-metabolic-magnet-system-in-adults-with-gastrointestinal-disorders-100617319","NCT07317076","GT Metabolic Magnet System in Adults With Gastrointestinal Disorders","Compression Anastomosis Using the GT Metabolic Magnet System in Adults With Gastrointestinal Disorders (GT Metabolic Magnet System Study)","Inclusion Criteria:\n\n* Indicated for gastrointestinal surgery requiring a gastric and\u002For small bowel anastomosis, without need for immediate lumen patency, and meets one of the following criteria:\n\n  1. Superior mesenteric artery syndrome (SMAS); OR\n  2. Gastric outlet obstruction (GOO); OR\n  3. Partial small bowel obstruction.\n* Meets the surgical clearance requirements as governed by the investigator's institution.\n* If a child-bearing female, subject must commit to not becoming pregnant and agree to use contraception for the duration of the study.\n\nExclusion Criteria:\n\n* Other gastrointestinal or abdominal surgeries planned concurrently or within the study follow-up period (e.g., bariatric surgery such as sleeve gastrectomy).\n* Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contraindicate the anastomosis or study procedure, including scarring and abnormal anatomy at the anastomosis sites.\n* Any anomaly precluding gastrointestinal access by gastroscope \u002F endoscope, catheters, and associated manipulation techniques for device placement.\n* Any condition or disease that precludes laparoscopic surgery.\n* Implantable pacemaker, defibrillator, other active and\u002For metallic implant that may interfere with or be adversely impacted by a temporary magnetic implant (Magnet System) and associated procedures.\n* Unhealed ulcers, bleeding lesions, tumor, diseased tissue or any other lesion at or distal to the target Magnet deployment sites.\n* Any need for immediate lumen patency while the anastomosis is formed.\n* History of prior or current malignancy.\n* Expected need for Magnetic Resonance Imaging (MRI) within the first 3 months post-procedure (or before if Magnet expulsion is confirmed radiologically).\n* Known allergies to the device components (including the biofragmentable material PGLA or similar compounds) or contrast media.\n* Pregnant, lactating, or planning pregnancy during the clinical investigation and follow up period.\n* Currently participating in an investigational drug, biologic, or medical device or other interventional clinical study.\n* Presence of other anatomic or comorbid conditions, or medical, social or psychological conditions that, in the investigator's opinion, could limit the participant's ability to participate in the clinical investigation or to comply with follow-up requirements.",{"count":83,"type":20},35,[23],"Evaluate the performance and safety of the GT Metabolic Magnet System for the creation of side-to-side compression anastomosis in the stomach and\u002For small bowel in conditions requiring an anastomosis as part of the underlying clinical treatment.",[26,87,88],"Small Bowel Obstruction","Superior Mesenteric Artery Syndrome",[62,63],"2026-05-18",{"date":92,"type":40},"2026-05-19",{"date":94,"type":40},"2025-12-09",{"date":96,"type":20},"2026-11",{"name":63,"class":73},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":107,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":116,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":74},"100424911","prospective-registry-of-therapeutic-endoscopic-ultrasound-100424911","NCT04813055","Prospective Registry Of Therapeutic EndoscopiC ulTrasound","PROTECT","Inclusion Criteria:\n\n* subjects candidate to therapeutic EUS (T-EUS) procedures for any underlying disease\n* subject eligible to T-EUS procedures but undergoing other non-EUS based endoscopic procedures, percutaneous or surgical procedures\n* 18 years old or older\n* able to provide an informed consent to inclusion.\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* inability or unwillingness to sign the informed consent form (ICF)\n* contra-indication for endoscopy or use of fluoroscopy",{"count":106,"type":20},510,"12 Months","OBSERVATIONAL","This registry aims to analyze long-term outcomes of therapeutic EUS (T-EUS) procedures, as well as to describe clinical and technical variables potentially predicting clinical success or adverse events, for a better selection of ideal candidates.\n\nThe study also includes standard alternatives to T-EUS procedures for outcomes comparison.",[26,111,112,113,114,115],"Biliary Obstruction","Acute Pancreatic Fluid Collection","Acute Pancreatitis With Infected Necrosis","Acute Cholecystitis","Chronic Pancreatitis",[117,118,119,120,121,122,123],"Endoscopic ultrasound","Therapeutic EUS","Interventional EUS","Biliary Drainage","Gastro-jejunostomy","Gallbladder Drainage","Endoscopy","2026-04-10",{"date":126,"type":40},"2026-04-13",{"date":128,"type":40},"2020-12-01",{"date":130,"type":20},"2026-12-31",{"name":132,"class":47},"Paolo Giorgio Arcidiacono, MD",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":142,"studyType":108,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100521585","management-of-malignant-gastric-outlet-obstruction-between-surgery-and-endoscopy-100521585","NCT06071507","Management of Malignant Gastric Outlet Obstruction Between Surgery and Endoscopy","GOOSE","Inclusion Criteria:\n\n* cyto-\u002Fhisto-logically confirmed pancreatic cancer\n* a maximum of 6 months from pancreatic cancer diagnosis and candidate to active treatment\n* stenosis causing gastric outlet obstruction (GOO) due to neoplastic invasion\u002Fcompression confirmed by radiology or endoscopy extending from the distal one third of the stomach or the duodenum\n* patients candidate to either ES or EUS-GE or s-GE\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* patients with benign or indeterminate gastrointestinal stenosis\n* patients with malignant GOO (mGOO) from neoplasia other than pancreatic cancer\n* candidates to upfront surgical resection or who already received curative pancreatic resection\n* patients who already received a treatment for mGOO\n* patients receiving an additional procedure for biliary drainage which might increase the risk of adverse events or hamper the assessment of quality of life; biliary drainage will be allowed if performed uneventfully (without adverse events) at least one day (endoscopic drainage) or one month (surgical hepaticojejunostomy) before mGOO treatment;\n* patients carrying any percutaneous drainage (such as percutaneous transhepatic biliary drainage or ascites drainage).\n* inability or unwillingness to sign the informed consent form (ICF)\n* contraindications to any active palliation of the mGOO, or indication to palliation through venting gastrostomy or nasogastric tube placement alone",{"count":141,"type":20},250,"24 Months","The aim of this observational study is to compare the outcomes of three different procedures performed for the management of malignant Gastric Outlet Obstruction due to Pancreatic Cancer.\n\nPatients who undergo:\n\n* Surgical gastroenterostomy\n* Endoscopic placement of a self-expanding metallic stent\n* EUS-guided gastroenterostomy in accordance with standard clinical practice, will be enrolled to evaluate potential differences between the procedures in terms of clinical success, eating experience, chemotherapy tolerance, and nutritional status during follow-up.\n\nParticipants will be asked to complete a quality of life questionnaire at baseline and during follow-up; however, no additional procedures will be conducted as a result of participation in the study.",[26,145],"Pancreatic Cancer",[147,148,149,150,151,152,34],"Enteral stent","Duodenal stent","Gastroenterostomy","EUS","Bypass","LAMS","2026-01-14",{"date":155,"type":40},"2026-01-15",{"date":157,"type":40},"2024-04-15",{"date":159,"type":20},"2027-12",{"name":161,"class":47},"IRCCS San Raffaele",5,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100488502","endoscopic-ultrasound-guided-large-diameter-lumen-apposing-metal-stent-gastro-gastrostomy-for-bypass-reversal-in-patients-with-roux-en-y-gastric-bypass-100488502","NCT05640947","Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass","Endoscopic Ultrasound-guided Large Diameter Lumen-apposing Metal Stent Gastro-gastrostomy for Bypass Reversal in Patients With Roux-en-y Gastric Bypass: a Proof of Concent Study","LABOR","Inclusion Criteria:\n\n* Group 1) patients needing any kind of parenteral nutritional support (eg. hypo- albuminemia, hypovitaminoses, mineral deficiencies,...) that can not be corrected by dietary intervention\u002Foral supplementation\n* Group 2) patients with persistent invalidating symptomatic dumping syndrome despite optimal dietary intervention (typical complaints are headache, sweating, trembling, weakness and feeling hungry).\n* Group 3) patients with a refractory marginal ulcers with stenosis of the gastrojejunostomy leading to feading difficulties.\n* Group 4) patients with F3 or F4 liver fibrosis and a tendency to decompensation after bypass surgery, as demonstrated by an increase in serum bilirubin\u002FINR and\u002For lowering of serum albumin.\n\nExclusion Criteria:\n\n1. Uncorrectable coagulopathy\n2. Presence of significant portal hypertension as demonstrated by 2.1) the presence of esophageal and\u002For gastric varices AND\u002FOR 2.2) a hepatic venous pressure gradient (if measured) equal to or more than 10mm Hg AND\u002FOR 2.3) the combination of\n\n   1. a platelet count \\\u003C150000\u002Fµl AND\n   2. liver stiffness measured by elastometry equal to or more than 20 kPa (Baveno guidelines).\n3. Pregnant women, breastfeeding women or women that can not assure adequate anticonception for the duration of the study (based on anamnesis).\n4. Karnofsky index less than 60\n5. Vulnerable patients",{"count":172,"type":20},20,[23],"The primary objective of this open-label pilot study is to investigate whether an endoscopically placed lumen apposing metal stent is an effective alternative to surgery in patients that have a clear indication for reversal of their gastric bypass.",[176,26,177,178,179],"Hypoglycemia","Steatohepatitis","Parenteral Support","Gastric Bypass","2025-10-03",{"date":182,"type":40},"2025-10-08",{"date":184,"type":40},"2023-01-30",{"date":186,"type":20},"2028-02",{"name":188,"class":47},"University Hospital, Ghent",2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":21,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100605387","novel-balloon-assisted-vs-direct-technique-in-eus-guided-gastroenterostomy-100605387","NCT07161856","Novel Balloon-Assisted vs Direct Technique in EUS-Guided Gastroenterostomy","Novel Balloon-Assisted vs Direct Technique in EUS-Guided Gastroenterostomy: A Prospective Multicenter RCT","Inclusion Criteria:\n\n* Age ranges from 18 to 80 years old\n* GOO patients caused by all reasons (including benign diseases such as ulcers or malignant tumors)\n* Not suitable for or cannot tolerate surgical operations and endoscopic intestinal stent implantation\n* There are no absolute contraindications for EUS-GE\n* Signed informed consents\n\nExclusion Criteria:\n\n* Pregnant and lactating women\n* Unable or refused to provide informed consents\n* Patients with cognitive impairment, aphasia, mental disorders, or other conditions that may affect the patient's cooperation\n* Patients with endoscopic contraindications, anesthesia contraindications, digestive tract perforation or abdominal cavity infection\n* The tumor invades the duodenum or the upper segment of the jejunum Individuals whom the investigator deems unsuitable for participation","80 Years",{"count":199,"type":20},272,[23],"Gastric outlet obstruction (GOO) refers to mechanical blockage at the pylorus or duodenum, most commonly caused by unresectable malignancies of the stomach, duodenum, or pancreas. At the time of diagnosis, the majority of lesions are no longer amenable to curative resection, and median survival ranges from only 11.3 to 21.3 weeks. Throughout the disease course, patients develop nausea, vomiting, and severe malnutrition, which markedly impair quality of life. Current strategies to relieve obstruction include endoscopic stent placement and surgical gastrojejunostomy; however, each is associated with distinct drawbacks, such as stent occlusion, prolonged operative times, and high complication rates.\n\nEndoscopic ultrasound-guided gastroenterostomy (EUS-GE) is a minimally invasive technique in which a gastric-jejunal anastomosis is created under real-time EUS guidance, bypassing the obstructed segment and establishing a gastrojejunal shortcut. Compared with conventional surgery or endoscopic luminal stenting, EUS-GE offers reduced procedural trauma and lower recurrence rates, providing GOO patients with an additional, less-invasive therapeutic option.\n\nThree main EUS-GE approaches have been described: the direct method, the balloon-assisted method, and the double-balloon-assisted method. The direct method requires large volumes of water instillation, posing hemodynamic risks in patients with cardiovascular or cerebrovascular disease. The double-balloon technique relies on expensive, specialized devices that have not yet been widely adopted. The conventional balloon-assisted method demands needle puncture of a partially inflated balloon, which compromises stability and can displace the target jejunum away from the gastric wall. All three techniques are technically demanding, limiting their broad clinical dissemination.\n\nThe investigators therefore designed and previously reported a dedicated single-balloon-assisted device specifically for EUS-GE. This novel system aims to shorten procedure time, reduce intraprocedural water volume, and enhance procedural safety. The present prospective, multicenter, randomized controlled trial was undertaken to validate the clinical efficacy and safety of this new single-balloon-assisted technique compared with the conventional direct water-injection method.",[26],"2025-09-08",{"date":205,"type":40},"2025-09-09",{"date":207,"type":20},"2025-09-01",{"date":209,"type":20},"2026-08-01",{"name":211,"class":47},"Changhai Hospital"]